References

1. Mozaffarian D, Benjamin EJ, Go AS, Arnet DK, Blaha MJ, et al. (2015) on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update A Report From the American Heart Association. Circulation 132: 000-000.
2. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, et al. (2013) on behalf of the American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6: 606-619.
3. Chang PP, Chambless LE, Shahar , Bertoni A, Russell SD, et al. (2014) Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study). Am J Cardiol 113: 504-510. View
4. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, et al. (2004) Trends in heart failure incidence and survival in a community-based population. JAMA 292: 344-350. View
5. National Center for Health Statistics. Mortality multiple cause micro-data files, 2011: public-use data file and documentation: NHLBI tabulations.
6. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2013) Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 127: e6-e245. View
7. Curtis LH, Greiner MA, Hammill BG, Kramer JM, Whellan DJ, et al. (2008) Early and long-term outcomes of heart failure in elderly persons, 2001- 2005. Arch Intern Med 168: 2481-2488. View
8. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, et al. (2013) American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Circ Heart Fail 6: 606-619. View
9. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33: 1787-1847. View
10. Yancy CW, Jessep M, Bozkurt B, Butler J, Casey DE Jr, et al. (2013) ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128: e240-e327. View
11. Quiroz R, Doros G, Shaw P, Liang CS, Gauthier DF, et al. (2014) Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort. Am J Cardiol 113: 691-696. View
12. Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, et al. (2006) Navigating the crossroads of coronary artery disease and heart failure. Circulation 114: 1202-1213. View
13. Chen Y, Duan C, Liu F, Shen S, Chen P, et al. (2014) Impact of etiology on the outcomes in heart failure patients treated with cardiac resynchronization therapy: a meta-analysis. PLoS One 9: e94614. View
14. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE (2002) Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a metaanalysis. J Am Coll Cardiol 39: 1151-1158. View
15. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, et al. (2007) Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 32: 375-410. View
16. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, et al. (2011) Coronaryartery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 364: 1607-1616. View
17. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, et al. (2011) Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 364: 1617-1625. View
18. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, et al. (2007) F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 50: 2002-2012. View
19. Braunwald E, Rutherford JD (1986) Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol 8: 1467-1470. View
20. Bonow RO (1996) Identification of viable myocardium. Circulation 94: 2674-2680. View
21. Bax JJ, Poldermans D, van der Wall EE (2004) Evaluation of hibernating myocardium. Heart 90: 1239-1240. View
22. Beanlands RSB, Ruddy TD, Maddahi J (2002) Myocardial viability. Principles and practices of positron emission tomography. In: Wahl RL, Buchanan JW, editors. Philadelphia: Lippincott, Williams & Wilkins; 2002, p334-350.
23. Bax JJ, Delgado V (2015) Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure. J Nucl Cardiol 22: 229-245. View
24. Nesto RW, Kowalchuk GJ (1987) The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia. Am J Cardiol 59: 23C-30C. View
25. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, et al. (1997) Accuracy currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 30: 1451-1460. View
26. Knuuti MJ, Nuutila P, Ruotsalainen U, Saraste M, Härkönen R, et al. (1992) Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 33: 1255-1262. View
27. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, et al. (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343: 1445-1453. View
28. Ichikawa Y, Sakuma H, Suzawa N, Kitagawa K, Makino K, et al. (2005) Late gadolinium-enhanced magnetic resonance imaging in acute and chronic myocardial infarction. Improved prediction of regional myocardial contraction in the chronic state by measuring thickness of nonenhanced myocardium. J Am Coll Cardiol 45: 901-909. View
29. D'Egidio G, Nichol G, Williams KA, Guo A, Garrard L, et al. (2009) Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging 2: 1060-1068. View
30. Bonow RO, Castelvecchio S2, Panza JA3, Berman DS4, Velazquez EJ5, et al. (2015) Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. JACC Cardiovasc Imaging 8: 1121-1129. View
31. Nijland F, Kamp O, Verhorst PM, de Voogt WG, Bosch HG, et al. (2002) Myocardial viability: impact on left ventricular dilatation after acute myocardial infarction. Heart 87: 17-22. View
32. Rizzello V, Poldermans D, Biagini E, Schinkel AFL, Boersma E, et al. (2009) Prognosis of patients with ischemic cardiomyopathy after coronary revascularization: relation to viability and improvement in left ventricular ejection fraction. Heart 95: 1273-1277. View
33. Bax JJ, Schinkel AF, Boersma E, Rizzello V, Elhendy A, et al. (2003) Early versus delayed revascularization in patients with ischemic cardiomyopathy and substantial viability: impact on outcome. Circulation 108 Suppl 1: II39- 42. View
34. Tarakji KG, Brunken R, McCarthy PM, Al-Chekakie MO, Abdel-Latif A, et al. (2006) Myocardial viability testing and effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation 113: 203- 207. View
35. Stewart RA, Szalewska D, She L, Lee KL, Drazner MH, et al. (2014) Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure). JACC Heart Fail 2: 335-343. View
36. Beanlands RSB, Ruddy TD, deKemp RA, Iwanochko RM, Coates G, et al. (2002) Positron Emission Tomography and recovery following revascularization (PARR-1): The importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am CollCardiol 40:1735-1743. View
37. Panza JA, Velazquez EJ, She L, Smith PK, Nicolau JC, et al. (2014) Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]. J Am Coll Cardiol 64: 553-561. View
38. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, et al. (2007) COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356: 1503-1516. View
39. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, et al. (2008) Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117: 1283-1291. View
40. Panza JA, Holly TA, Asch FM, She L, Pallikka PA, et al. (2013) Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am CollCardiol 61: 1860-1870. View
41. Abraham A, Nichol G, Williams KA, Guo A, deKemp RA, et al. (2010) 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med 51: 567-574. View
42. Inaba Y, Chen JA, Bergmann SR (2010) Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: A meta-analysis. J Nucl Cardiol 17: 646-654. View
43. Chen Y, Duan C, Liu F, Shen S, Chen P, et al. (2014) Impact of etiology on the outcomes in heart failure patients treated with cardiac resynchronization therapy: a meta-analysis. PLoS One 9: e94614. View
44. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, et al. (2002) Cardiac resynchronization in chronic heart failure. N Engl J Med 346: 1845- 1853. View
45. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, et al. (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350: 2140- 2150. View
46. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, et al. (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352: 1539-1549. View
47. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, et al. (2008) Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 117: 2608-2616. View
48. Boogers MM, Van Kriekinge SD, Henneman MM, Ypenburg C, Van Bommel RJ, et al. (2009) Quantitative gated SPECT-derived phase analysis on gated myocardial perfusion SPECT detects left ventricular dyssynchrony and predicts response to cardiac resynchronization therapy. J Nucl Med 50: 718-725. View
49. Adelstein EC, Tanaka H, Soman P, Miske G, Haberman SC, et al. (2011) Impact of scar burden by single-photon emission computed tomography myocardial perfusion imaging on patient outcomes following cardiac resynchronization therapy. Eur Heart J 32: 93-103. View
50. Lin X, Xu H, Zhao X, Chen J (2014) Site of latest mechanical activation as assessed by SPECT myocardial perfusion imaging in ischemic and dilated cardiomyopathy patients with LBBB. Eur J Nucl Med Mil Imaging 41: 1232- 1239. View
51. Bax JJ, Abraham T, Barold SS, Breithardt OA, Fung JW, et al. (2005) Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol 46: 2153-2167. View
52. Chen J, Garcia EV, Folks RD, Cooke CD, Faber TL, et al. (2005) Onset of left ventricular mechanical contraction as determined by phase analysis of ECG-gated myocardial perfusion SPECT imaging: development of a diagnostic tool for assessment of cardiac mechanical dyssynchrony. J NuclCardiol 12: 687-95. View
53. Ypenburg C, Schalij MJ, Bleeker GB, Steendijk P, Boersma E, et al. (2007) Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients. Eur Heart J 28: 33-41. View
54. Lehner S, Uebleis C, Schüßler F, Haug A, Kääb S, et al. (2013) The amount of viable and dyssynchronous myocardium is associated with response to cardiac resynchronization therapy: initial clinical results using multiparametric ECG-gated [18F]FDG PET. Eur J Nucl Med Mol Imaging 40: 1876-1883. View
55. Marsan NA, Westenberg JJ, Ypenburg C, van Bommel RJ, Roes S, et al. Magnetic resonance imaging and response to cardiac resynchronization therapy: relative merits of left ventricular dyssynchrony and scar tissue. Eur Heart J 30: 2360-1377. View
56. Ypenburg C, van Bommel RJ, Delgado V, Mollema SA, Bleeker GB, et al. (2008) Optimal left ventricular lead position predicts reverse remodeling and survival after cardiac resynchronization therapy. J Am Coll Cardiol 52: 1402-1409. View
57. Khan FZ, Virdee MS, Fynn SP, Dutka DP (2009) Left ventricular lead placement in cardiac resynchronization therapy: where and how? Europace 11: 554-561. View
58. Bax JJ, Abraham T, Barold SS, Breithardt OA, Fung JW, et al. (2005) Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol 46: 2168-2182. View